The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer

被引：0
|
作者：
Suh, Kangho
Carlson, Josh John
Xia, Fang
Williamson, Todd E.
Sullivan, Sean D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
41
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Yuan, Chengbo
    Kurtinecz, Milena
    Pan, Xiaoyun
    Vassilev, Zdravko
    Pisa, Federica
    Ostojic, Helene
    CANCERS, 2025, 17 (06)
  • [22] Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib.
    Drilon, Alexander
    Kummar, Shivaani
    Albert, Catherine M.
    Nagasubramanian, Ramamoorthy
    Hechtman, Jaclyn F.
    Reeves, John A.
    Beckmann, Georg
    Rudolph, Marion
    Wierzbinska, Justyna A.
    Dima, Laura
    Brega, Nicoletta
    Laetsch, Theodore W.
    Hong, David S.
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
    Unseld, Matthias
    Drimmel, Magdalena
    Siebenhuner, Alexander
    Gleiss, Andreas
    Bianconi, Daniela
    Kieler, Markus
    Scheithaueer, Werner
    Winder, Thomas
    Prager, Gerald W.
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : 274 - 279
  • [24] Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study
    Bazarbashi, Shouki
    Alkhatib, Radwan
    Aseafan, Mohamed
    Tuleimat, Yasmin
    Abdel-Aziz, Nashwa
    Mahrous, Mervat
    Elsamany, Sherif
    Elhassan, Tusneem
    Alghamdi, Mohammed
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [25] Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
    Patel, Anuj K.
    Abhyankar, Ritika
    Brais, Lauren K.
    Duh, Mei Sheng
    Barghout, Victoria E.
    Huynh, Lynn
    Yenikomshian, Mihran A.
    Ng, Kimmie
    Fuchs, Charles S.
    ONCOLOGIST, 2021, : e2161 - e2169
  • [26] Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment
    Signorelli, C.
    Schirripa, M.
    Chilelli, M. G.
    Calegari, M. A.
    Basso, M.
    Anghelone, A.
    Lucchetti, J.
    Minelli, A.
    Angotti, L.
    Morelli, C.
    Dell'Aquila, E.
    Cosimati, A.
    Gemma, D.
    Ribelli, M.
    Corsi, D. C.
    Arrivi, G.
    Zoratto, F.
    Morandi, M. G.
    Santamaria, F.
    Saltarelli, R.
    Ruggeri, E. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S719 - S719
  • [27] Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study
    Kotaka, M.
    Ogata, M.
    Ogata, T.
    Hatachi, Y.
    Yasui, H.
    Kato, T.
    Tsuji, A.
    Satake, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real-World Evidence From Regorafenib and Trifluridine/Tipiracil Use
    Chang, Ya-Wen
    Kuo, Chun-Nan
    Chang, Chia-Lun
    Hsu, Jason C.
    Ko, Yu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025,
  • [29] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. ENTRECTINIB FOR TREATMENT OF METASTATIC FUSION-POSITIVE CANCERS IN CHILDREN AND YOUNG ADULTS
    Suh, K.
    Kang, A.
    Singh, R.
    Williamson, T.
    Sullivan, S.
    VALUE IN HEALTH, 2024, 27 (06) : S44 - S45
  • [30] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF METASTATIC NTRKGENE FUSION-POSITIVE CANCERS
    Suh, K.
    Kang, A.
    Ko, G.
    Williamson, T.
    Liao, N.
    Sullivan, S.
    VALUE IN HEALTH, 2023, 26 (06) : S55 - S55
12345